Testing SRP-1005 in early-stage Huntington's disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This first-in-human study tests whether SRP-1005, a new drug, is safe and tolerable in people with early Huntington's disease. The drug is designed to reduce levels of a harmful protein in the brain that causes Huntington's symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Genetic confirmation that you have Huntington's disease (HTT gene with 40+ CAG repeats)
- Your Huntington's disease is in Stage 2 or early Stage 3 (mild symptoms, some functional impact)
- Willingness to use effective birth control for the duration of the study plus 90 days after
- No major neurological or serious medical conditions besides Huntington's
- No active or chronic infections (HIV, hepatitis B or C)
- Able to safely undergo lumbar puncture (spinal tap) and MRI scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ALN-HTT02 for people with Huntington's disease. The goal is to see if it can help manage symptoms. Participants must have stage 2 or early stage 3 Huntington's disease.
This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.
This study gathers small samples of spinal fluid from people affected by Huntington’s disease. Researchers use these samples to better understand the disease and support future treatments. If you join, you’ll need to follow their sample and visit schedule.
This study tests a new medicine called SRP-1001 to see if it can help people with a type of muscular dystrophy called FSHD1. It aims to slow down muscle weakness and improve quality of life.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Hear when a new Huntington's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.